PRRT

Understanding Results

Typically most cancer patients want to understand the statistics associated with survival for their particular form of cancer. The survival rate and other measures in terms of months or years is almost always part of any report on the efficacy of a treatment. For patients being treated for a NET cancer there are several measures of treatment efficacy that are important when considering a treatment.

When you and your doctor are evaluating which treatment modality is right for you, be sure to compare the Time to Progression/Progression Free Survival and Duration of Therapy Response for PRRT to other modalities under consideration.

Also of interest is the measurement called Overall Survival (OS).

Time to Progression

What are the Risks?

As with most, if not all, of the treatment options open to neuroendocrine tumor patients, there are risks associated with using PRRT to treat metastasized tumors. The greatest risks arise from radiation toxicity affecting three things: 1) the blood system producing Red Blood Cells, White Blood Cells and Blood Platelets, 2) the functioning of the kidneys and 3) the functioning of the liver.

At one time kidney impairment or renal insufficiency was a significant risk, but as

This is a partial list of centers that offer PRRT to patients from North America- Please feel free to contact us to add other centers to the list.  As with any medical decision it is advisable to contact or interview more than one provider and understand the differences in approach between centers offering PRRT therapy.

This email address is being protected from spambots. You need JavaScript enabled to view it., Clinical Center Kragujevac - PRRT for patients from Serbia, Montenegro, Bosnia and Herzegovina and Kosova region will accept patinets from

This is a partial list of centers that offer PET/CT using Galuim 68.  Please feel free to contact us to add other centers to the list. 

Peptide Receptor Radionuclide Therapy (PRRT) will not work on all neuroendocrine tumors. For this treatment to work you MUST have somatostatin receptors in your tumors. When a somatostatin analog (like a form of octreotide) is combined with a radionuclide such as Lutetium-177 (LU177) or Yttrium-90 (Y90), it has a strong affinity for the somatostatin receptor subtype-2 that can exist in the NET tumor. This means that the radioactive material put in the body for the treatment will be absorbed

Subcategories